Pharmaceutical Technology on MSN
Aktis Oncology kicks 2026 IPO cycle off with $210m target
"Aktis Oncology kicks 2026 IPO cycle off with $210m target" was originally created and published by Pharmaceutical Technology ...
Renaissance IPO ETF (IPO) is rated a buy, anticipating a surge in major IPOs through 2026 to fuel renewed investor interest.
Opinion
8hOpinion
BCCL IPO: Cheap on paper, costly in a downcycle; why Coal India may be the smarter pick
BCCL's IPO may appear cheap, but Coal India offers more stable, diversified returns, making it the smarter investment choice.
Crypto and AI-based initial public offerings last year reportedly dragged down the performance of all US public debuts to ...
A potential initial public offering (IPO) next year by cryptocurrency exchange Kraken may attract fresh capital from traditional finance (TradFi) investors. Bitcoin recorded an all-time high price ...
Kotak’s Sanjeev Prasad says only ’15-20% Of IPO funds used for asset creation’ — 5 key 2026 insights
IPO funds used mainly for promoter exits, not assets—see Sanjeev Prasad’s 2026 outlook and market drivers. Read key insights ...
Over the next 18 months, more than 48 Indian startups are set to enter the public markets. The list includes some of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback